Skip to main content
OpenTrials
Completed

NCT Number: NCT01835015

Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular Degeneration

The purpose of this study is to evaluate the safety, tolerability, and serum pharmacokinetics of CLG561 in subjects with advanced age-related macular degeneration (AMD).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age-Related Macular Degeneration Choroid Diseases Choroidal Neovascularization Eye Diseases Geographic Atrophy Macular Degeneration Metaplasia Neovascularization, Pathologic Pathologic Processes Pathological Conditions, Signs and Symptoms Retinal Degeneration Retinal Diseases Uveal Diseases

Age range

55 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

About this study

Subjects were divided into 5 cohorts, with the subjects in each cohort being administered a single IVT dose of CLG561 in 1 of 5 concentration levels A-E, where A=lowest and E=highest. All subjects received active CLG561. Progress from one cohort to the next was time-lagged to allow for safety review. Dosing was also time-lagged within each cohort. Only one eye (designated as the study eye) was dosed per subject. Post-dose safety assessments and ocular examination occurred immediately after the IVT injection and continued throughout the outpatient visits at pre-determined timepoints. Collection of post-injection blood samples began after the IVT injection at pre-determined timepoints. Subjects were followed for up to 84 days.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of age-related macular degeneration in study eye, as specified in protocol.
  • Poor visual acuity in study eye, as specified in protocol.
  • Willing to receive meningitis and pneumonia vaccinations at least 2 weeks prior to study treatment.
  • Females must be post-menopausal and/or surgically sterile.
  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

  • Treatments to the study eye within 28 days prior to study treatment, as specified in protocol.
  • Any disease or medication expected to cause systemic or ocular immunosuppression.
  • Participation in another interventional clinical study or use of any experimental treatment for AMD within 12 weeks prior to study treatment.
  • Other protocol-defined exclusion criteria may apply.

Treatment and study plan

CLG561

Drug

Administered by intravitreal injection, Day 1

Primary outcomes

  1. Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) by Visit - Study Eye

    Time frame: Baseline, Day 2, Day 4, Day 15, Day 29, Day 57, Day 85

    BCVA (with spectacles or other visual corrective devices) using Early Treatment Diabetic Retinopathy Study (ETDRS) testing was reported in letters read correctly. Improvement of BCVA was defined as an increase (gain) in letters read from the baseline assessment. One eye (study eye) contributed to the analysis.

  2. Mean Intra-Ocular Pressure (IOP) by Visit - Study Eye

    Time frame: Baseline, Day 1, Day 2, Day 4, Day 15, Day 29, Day 57, Day 85

    IOP was measured by Goldmann applanation tonometry or tonopen, at the discretion of the Investigator, and reported in mmHg (millimeters of mercury). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye (study eye) contributed to the analysis.

  3. Number of Subjects With Change From Normal to Abnormal in Fundus Examination at Any Post-Therapy Visit as Compared to Baseline Assessment

    Time frame: Baseline, Day 2, Day 4, Day 8, Day 15, Day 29, Day 57, Day 85

    A dilated fundus examination was performed to evaluate the health of the retina, macula, choroid, and optic nerve. Subjects having a normal baseline evaluation were examined at subsequent visits, and any change from normal to abnormal was recorded. Criteria for reclassifying from normal to abnormal were left to the opinion of the investigators. One eye (study eye) contributed to the analysis. None of the abnormalities were deemed related to the study medication.

  4. Number of Subjects With a Change From Normal to Abnormal in Ocular Signs at Any Post-Therapy Visit as Compared to Baseline Assessment

    Time frame: Baseline, Day 2, Day 4, Day 8, Day 15, Day 29, Day 57, Day 85

    A slit-lamp biomicroscopy examination was performed to evaluate the anterior segment of the eye. Subjects having a normal baseline evaluation were examined at subsequent visits, and any change from normal to abnormal was recorded. Criteria for reclassifying from normal to abnormal were left to the opinion of the investigators. One eye (study eye) contributed to the analysis. None of the abnormalities were deemed related to the study medication.

Secondary outcomes

  1. Area Under the Serum Concentration-time Curve (AUC) From Time Zero to All [AUC(0-all)]

    Time frame: Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85

    Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental pharmacokinetic (PK) method.

  2. Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-last)]

    Time frame: Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85

    Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental PK method.

  3. Time to Reach the Maximum Serum Concentration After Drug Administration (Tmax)

    Time frame: Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85

    Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental PK method.

  4. Dose Normalized Observed Maximum Serum Concentration Following Drug Administration (Cmax/D)

    Time frame: Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85

    Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental PK method.

  5. Dose-normalized Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-last)/D]

    Time frame: Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85

    Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. These data were analyzed using a noncompartmental PK method.

  6. Area Under the Serum Concentration-time Curve From Time Zero to Time "t" Where t is a Defined Time Point After Administration [AUC(0-t)]

    Time frame: Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85

    Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method.

  7. Terminal Elimination Half-life (T½)

    Time frame: Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85

    Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method.

  8. The Apparent Volume of Distribution During the Terminal Elimination Phase Following Extravascular Administration (Vz/F)

    Time frame: Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85

    Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method.

  9. Apparent Systemic (or Total Body) Clearance From Serum Following Extravascular Administration (CL/F)

    Time frame: Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29, Day 57, Day 85

    Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method.

Sponsors and collaborators

Lead sponsor

Alcon Research

Industry

Registry information

Official study title

A Multi-Center, Open-Label, Single Ascending Dose Study To Assess the Safety, Tolerability, and Serum Pharmacokinetics of Intravitreal CLG561 in Subjects With Advanced Age-Related Macular Degeneration

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Apr 18, 2013
Registry last updated
Mar 25, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.